Electra Therapeutics
electra-therapeutics.com
Actively hiring
Biotechnology
Science & Engineering
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
The Blueprint for Novel Science. Translating Differentiated Biology into Transformational Medicines.
News
Electra Therapeutics Prices $350 Million In Upsized IPO To Advance Precision Medicines For Immune Diseases And Cancer
Electra Therapeutics has priced an upsized $350 million initial public offering, giving the late clinical-stage biopharmaceutical company substantial new capital as it advances a pipeline of precision medicines for immune-mediated diseases and cancer.
Read more
Report
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer,
Read more
Report
Dear Future Electra Therapeutics Stock Fans, Mark Your Calendars for Sept. 18
Electra Therapeutics is heading toward a Nasdaq listing with a promising clinical pipeline, a capital-intensive path ahead, and key milestones on investors' radar.
Read more
Report
Pro access
Upgrade to see all 19 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.